Allogene Therapeutics Reports Q3 2025 Net Loss of $41.4M, Cash of $277.1M

Allogene Therapeutics, Inc.

2025-Q3 EPS reported -$0.70 vs consensus -$0.23 ▼ miss (-207.4%)

Q3 2025 net loss $41.4M ($0.19 per share), cash $277.1M, cash runway into 2H 2027.
Phase 2 ALPHA3 trial for cema-cel in LBCL on track for futility analysis in 1H 2026.
Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease enrolling, proof-of-concept data expected 1H 2026.
Phase 1 TRAVERSE trial for ALLO-316 in RCC shows durable responses; next phase under evaluation.
Additional ALPHA3 trial sites in Australia and South Korea expected to open early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.